Lennox-Gastaut syndrome: treatment approach when VPA plus LTG does not provide adequate seizure control

In patients with Lennox-Gastaut syndrome whose seizures remain inadequately controlled on valproate (VPA) and lamotrigine (LTG), a structured evidence-based protocol defines the recommended next therapeutic step and the adjustments that should follow.

Clinical situation Lennox-Gastaut syndrome with persistent seizures despite combination therapy with VPA and LTG. The current regimen has not achieved adequate seizure control, and escalation is indicated.

Approach — partial overview The protocol calls for initiating an adjunctive anti-seizure medication alongside the existing background therapy, followed by specified sequential adjustments to the background regimen. The full protocol details which agent to add and precisely how the background medications should be modified in response.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1002/epi4.13075

If VPA plus LTG does not provide adequate seizure control, RUF should be initiated as adjunctive therapy.

Once RUF has been initiated, attempts should be made to discontinue either VPA or LTG, and, if VPA is discontinued, the LTG dose should be increased.

View source ↗